image

SEC Filing Details

We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.
SEC Filing Details

Document Details

Form
Filing Date
September 24, 2020
Document Date
September 24, 2020
Form Description
Initial filing by director officer or owner of more than ten percent.
Filing Group
3,4,5
Company
Prelude Therapeutics
Issuer
PRELUDE THERAPEUTICS INC
Filer
ORBIMED ADVISORS LLC